SSY Group Full Year 2023 Earnings: Revenues Disappoint

SSY Group (HKG:2005) Full Year 2023 Results

Key Financial Results

• Revenue: HK$6.46b (flat on FY 2022).
• Net income: HK$1.32b (up 17% from FY 2022).
• Profit margin: 20% (up from 18% in FY 2022).
• EPS: HK$0.44 (up from HK$0.38 in FY 2022).

2005 Post-Clinical Trial Products

• Approved (during full year): 86.

All figures shown in the chart above are for the trailing 12 month (TTM) period

SSY Group Revenues Disappoint

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 3.9% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for SSY Group you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.